Skip to main content
. 2018 Oct 2;10(10):1399. doi: 10.3390/nu10101399

Figure 2.

Figure 2

Figure 2

Topical treatment of PG102 alleviates imiquimod (IMQ)-induced psoriasis-like symptoms. (A) Experimental scheme (B) Photo of dorsal skin of Control (DMSO only), Vehicle (IMQ + DMSO), PG102 (IMQ + PG102 100 mg/kg) and Dexamethasone (IMQ + Dex 1 mg/kg) treated mice. (C) Psoriasis Area and Severity Index (PASI) scoring. (D) Hematoxylin-eosin (H&E) staining of dorsal skin (200×). (E) Interleukin (IL)-17A protein level from phorbol 12-myristate 13-acetate (PMA)/ionomycin-restimulated cells isolated from draining lymph nodes. (F) Change in body weight. Representative results from at least three independent experiments are shown (n = 3–4). The data are shown as the mean ± standard error of mean (SEM). ## p < 0.01, #### p < 0.0001 versus Control group; * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 versus vehicle group.